NewAmsterdam Pharma Company NAMS Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's stock-based comp?
- NewAmsterdam Pharma Company (NAMS) reported stock-based comp of $18M in Q1 2026.
- How has NewAmsterdam Pharma Company's stock-based comp changed year-over-year?
- NewAmsterdam Pharma Company's stock-based comp increased by 18.3% year-over-year, from $15.21M to $18M.
- What is the long-term trend for NewAmsterdam Pharma Company's stock-based comp?
- Over 4 years (2021 to 2025), NewAmsterdam Pharma Company's stock-based comp has grown at a 162.9% compound annual growth rate (CAGR), from $1.24M to $59.43M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.